Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Gage

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Clinical Pharmacology and Therapeutics|September 9, 2011
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingJ A Johnson, L Gong, M Whirl-Carrillo, et al.
The Pharmacogenomics Journal|May 25, 2011
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study designE J Do, P Lenzini, C S Eby, et al.
Circulation|April 1, 2009
Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding ScoreSumeet Subherwal, Richard G Bach, Anita Y Chen, et al.
Pharmacogenomics|December 19, 2014
Genotype and risk of major bleeding during warfarin treatmentVivian K Kawai, Andrew Cunningham, Susan I Vear, et al.
Clinical Pharmacology and Therapeutics|February 2, 2022
Warfarin Dosing in Patients With CYP2C9*5 Variant AllelesKathryn J Lindley, Nita A Limdi, Larisa H Cavallari, et al.
Annals of Internal Medicine|June 30, 2025
Catheter and Surgical Ablation for Atrial Fibrillation : A Systematic Review and Meta-analysisBryce Montané, Shiyang Zhang, Jonathan D Wolfe, et al.
Clinical Pharmacology and Therapeutics|February 16, 2017
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 UpdateJ A Johnson, K E Caudle, L Gong, et al.
Clinical Pharmacology and Therapeutics|March 5, 2010
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African AmericansD Voora, D C Koboldt, C R King, et al.
Heart (British Cardiac Society)|June 4, 2015
Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacementBrian R Lindman, Jared G Breyley, Joel D Schilling, et al.
Blood|February 6, 2008
CYP4F2 genetic variant alters required warfarin doseMichael D Caldwell, Tarif Awad, Julie A Johnson, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Clinical Pharmacology and Therapeutics|September 9, 2011
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingJ A Johnson, L Gong, M Whirl-Carrillo, et al.
The Pharmacogenomics Journal|May 25, 2011
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study designE J Do, P Lenzini, C S Eby, et al.
Circulation|April 1, 2009
Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding ScoreSumeet Subherwal, Richard G Bach, Anita Y Chen, et al.
Pharmacogenomics|December 19, 2014
Genotype and risk of major bleeding during warfarin treatmentVivian K Kawai, Andrew Cunningham, Susan I Vear, et al.
Clinical Pharmacology and Therapeutics|February 2, 2022
Warfarin Dosing in Patients With CYP2C9*5 Variant AllelesKathryn J Lindley, Nita A Limdi, Larisa H Cavallari, et al.
Annals of Internal Medicine|June 30, 2025
Catheter and Surgical Ablation for Atrial Fibrillation : A Systematic Review and Meta-analysisBryce Montané, Shiyang Zhang, Jonathan D Wolfe, et al.
Clinical Pharmacology and Therapeutics|February 16, 2017
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 UpdateJ A Johnson, K E Caudle, L Gong, et al.
Clinical Pharmacology and Therapeutics|March 5, 2010
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African AmericansD Voora, D C Koboldt, C R King, et al.
Heart (British Cardiac Society)|June 4, 2015
Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacementBrian R Lindman, Jared G Breyley, Joel D Schilling, et al.
Blood|February 6, 2008
CYP4F2 genetic variant alters required warfarin doseMichael D Caldwell, Tarif Awad, Julie A Johnson, et al.
Pageof 15